Phase II exploratory study of brostallicin PNU-166196A as third/fourth line chemoterapy in adult patients with advanced/metastatic colorectal cancer CRC .

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-004200-36-IT

Enrollment

Registered

2006-03-14

Start date

2005-12-02

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Use for the treatment of advanced/metastatic colorectal cancer, as third/fourth line chemioterapy. MedDRA version: 6.1 Level: HLT Classification code 10010023

Interventions

Product Name: Brostallicin Product Code: PNU-166196A Pharmaceutical Form: Powder for solution for injection CAS Number: 203258-60-0 Current Sponsor code: PNU-166196A Concentration unit: mg milligram(s

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026